sublingual semaglutide reddit Semaglutide Sublingual 1mg/ml | NextGenRx

Diabetes, Obesity, and Metabolism, 20(Suppl 1), 68-73

Khaleghi-Mehr M, Delshad A-A, Shafie-Damavandi S, Roghani M

It is the difference between a protocol you can evaluate and one where you are guessing whether it is working

#ambleptnr #joinamble #glp1 #glp1community #whatnow Last dayyy

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status